According to the 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5), biological markers (especially HR and HER2) should be reassessed at least once in the metastatic setting if clinically feasible as discordance between primary biomarker profiles of primary and metastatic breast cancer is well documented. Depending on the metastasis site, technical considerations may need to be discussed with the pathologist.
Learn more about breast cancer treatment protocols.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Fast Five Quiz: Are You Prepared to Confront Metastatic Breast Cancer? - Medscape - Dec 21, 2021.
Comments